Zentalis Pharmaceuticals, Inc. (ZNTL) Tops Q2 EPS by 17c
Tweet
Share
E-mailGet Alerts ZNTL Hot Sheet
Join SI Premium – FREE
Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) reported Q2 EPS of ($0.37), $0.17 better than the analyst estimate of ($0.54).
For earnings history and earnings-related data on Zentalis Pharmaceuticals, Inc. (ZNTL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pizza Hut CEO Aaron Powell resigns
- Palo Alto Networks (PANW) Tops Q4 EPS by 4c, Offers Guidance
- Blue Star Gold plans private placement and debt settlement
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
